Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
10635 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 5743
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Ablation Treatment with FARAPULSE™ Pulsed Field Ablation (PFA) System… NCT07925359 · NAVigate-ULTRA — The Evaluation of User Experience With FARAVIEW™ Technology of… | Maladie coronarienne | À vérifier | Non applicable | NOT_YET_RECRUITING | The objective of this study is to obtain experience with new and modified… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:06 | Détail |
| SESAME Procedure NCT07806149 · NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective… | Maladie coronarienne | Traitement symptomatique | Non applicable | NOT_YET_RECRUITING | This is an early study of a catheter-based minimally invasive procedure ca… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:06 | Détail |
| Topical cyanoacrylate tissue adhesive NCT07926191 · Tissue Adhesive Versus Figure-of-Eight Suture for Femoral Venous Closure After E… | Maladie coronarienne | Thérapie génique | À vérifier | NOT_YET_RECRUITING | In July 2026 the electrophysiology laboratory of a Czech tertiary cardiolo… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:06 | Détail |
| Truvaga Plus NCT07926945 · U54: nVNS RCT — Effects of nVNS on Stress Reactivity in IBS | Maladie coronarienne | Traitement symptomatique | Non applicable | NOT_YET_RECRUITING | Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interact… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:06 | Détail |
| Capstan Compass Robotic System for Transcatheter Mitral Valve Replace… NCT07917208 · Early Feasibility Study of the Capstan Medical TMVR System | Maladie coronarienne | Traitement symptomatique | Non applicable | RECRUITING | This early feasibility study is evaluating the safety and performance of t… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Discontinuation of aspirin (ATC-code B01AC06 and N02BA01) NCT07854795 · RELEASE-Norway — Reconsidering Long-Term Apirin in the Elderly in Secondary Prev… | Maladie coronarienne | À vérifier | Phase 4 | NOT_YET_RECRUITING | Lifelong aspirin has been a cornerstone of secondary prevention after coro… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Extracorporeal Shock Wave Therapy NCT07068399 · CSWT — Use of Shock Wave Therapy for Neo-Vascularisation in Non-critical Coronar… | Maladie coronarienne | Traitement symptomatique | Non applicable | RECRUITING | This randomized single-blind controlled trial aims to compare the effectiv… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Modified ultrafiltration NCT00246779 · A Study of the Effect of Blinding in a Trial of Blood Filtration During Heart Su… | Maladie coronarienne | À vérifier | Non applicable | COMPLETED | Cardiac surgery is a major consumer of blood products worldwide. The natur… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Naproxen NCT07549490 · Human Experimental Models of Pain (HEMP) | Maladie coronarienne | Immunomodulation · Traitement symptomatique | Non applicable | NOT_YET_RECRUITING | This pilot study will test an innovative way to establish how pain medicin… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Prescription of Aspirin NCT07524335 · ASCAD-P — Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Con… | Maladie coronarienne | À vérifier | Phase 3 | RECRUITING | In patients with subclinical coronary artery disease, the ASCAD-P study ai… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Pulmonary Vein Isolation NCT06402617 · RETRO-AF — Ablation of Focal Activation in Atrial Fibrillation | Maladie coronarienne | Ralentissement de la progression | Non applicable | RECRUITING | Atrial Fibrillation (AF) and Heart Failure (HF) are colliding global cardi… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Serratus Posterior Superior Intercostal Plane Block With Bupivacaine NCT07588230 · Serratus Posterior Superior Intercostal Plane Block in Minimally Invasive Cardia… | Maladie coronarienne | Traitement symptomatique | Non applicable | RECRUITING | This randomized, double-blind, placebo-controlled study aims to evaluate t… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| TAVI NCT07926022 · TAVI and PCI in Comparison to SAVR and CABG in Low and Intermediate Risk Patient… | Maladie coronarienne | À vérifier | À vérifier | RECRUITING | \# WHAT IS THIS STUDY ABOUT? This study compares two different treatment a… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| This study involved an auxillary CE-marked medical device (implantabl… NCT07545512 · ODISSEY — ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Car… | Maladie coronarienne | Traitement symptomatique | Non applicable | RECRUITING | Although advances in treatment and patient management have considerably im… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Evolocumab NCT05284747 · EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction | Maladie coronarienne | À vérifier | Phase 4 | ACTIVE_NOT_RECRUITING | The primary objective of this study is to evaluate the effectiveness of ea… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:04 | Détail |
| Microaxial flow pump (left ventricular assist device) NCT07762560 · DOUBLE-SHOCK — Routine Microaxial Heart Pump Support and Protocolized Pulmonary… | Maladie coronarienne | Thérapie génique | Non applicable | RECRUITING | The goal of this clinical trial is to learn which treatment strategies imp… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:04 | Détail |
| No aspirin (Prasugurel monotherapy) NCT05709626 · PREMIUM — PRasugrEl Monotherapy Following prImary percUtaneous Coronary Interven… | Maladie coronarienne | À vérifier | Phase 4 | COMPLETED | The aim of this study is to evaluate the safety of prasugrel monotherapy w… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:04 | Détail |
| Percutaneous Mechanical Circulatory Support NCT06445608 · PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm | Maladie coronarienne | À vérifier | Non applicable | RECRUITING | This purpose of this trial is to demonstrate 30 day safety and effectivene… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:04 | Détail |
| 26G Needle NCT07926113 · MASS-NEEDLE — Comparison of 26G and 30G Needles for Masseter Trigger Point Injec… | Myopathies | Traitement symptomatique | Non applicable | NOT_YET_RECRUITING | This randomized split-face study aims to compare the effects of 26G and 30… À vérifier | ClinicalTrials.gov 2026-11-09 21:02:59 | Détail |
| ABSK021 NCT04192344 · A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in… | Myopathies | À vérifier | Phase 1 | RECRUITING | This is an open-label phase 1 study to determine the safety and tolebility… À vérifier | ClinicalTrials.gov 2026-11-09 21:02:59 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4871
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Same Admission Hybrid Treatment of Primary Upper Extremity Deep Venou… Venous PTA · PMID 32795648 | Sclérose en plaques | Ralentissement de la progression · Traitement symptomatique | Publication | PubMed | Voir la publication source Multiple algorithms exist for treating acute primary upper extremity deep venous thrombosis (pUEDVT) caused by venous t… | Annals of vascular surgery 2026-08-16 13:01:43 | Source |
| Impact of infrared moxibustion for patients with mild hyperlipidemia:… Early Highly Effective Therapies Group · PMID 42080526 | Sclérose en plaques | Thérapie génique | Publication | PubMed | Voir la publication source Hyperlipidemia serves as a significant risk factor for cardiovascular diseases and cognitive impairment, making early i… | Annals of medicine 2026-08-16 13:01:41 | Source |
| Intravenous immunotherapy with Der p 1-containing nanoparticles allev… Escalation Therapies Group · PMID 41805230 | Sclérose en plaques | Immunomodulation · Traitement symptomatique | Publication | PubMed | Voir la publication source Subcutaneous immunotherapy has several limitations, including the long dose escalation period, frequent injections and… | Human vaccines & immunotherapeutics 2026-08-16 13:01:41 | Source |
| Management of moderate-to-highly exuding leg ulcers with polyacrylate… Early Highly Effective Therapies Group · PMID 41776171 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source This study evaluates the incremental cost‑effectiveness and budget impact of polyacrylate Superabsorbent (SAP) dressing… | Journal of medical economics 2026-08-16 13:01:41 | Source |
| Psychiatric Outcomes of Antiseizure Medications in Newly Diagnosed Fo… Early Highly Effective Therapies Group · PMID 42574692 | Sclérose en plaques | Thérapie génique | Publication | PubMed | Voir la publication source Psychiatric comorbidities are highly prevalent in people with epilepsy, which adversely affect treatment outcomes. The… | Neurology. Clinical practice 2026-08-16 13:01:41 | Source |
| Safety and immunogenicity of an investigational mRNA-lipid nanopartic… Escalation Therapies Group · PMID 41701031 | Sclérose en plaques | Ralentissement de la progression · Thérapie génique | Publication | PubMed | Voir la publication source This first-in-human, randomized, controlled, phase 1 proof-of-principle study evaluated the safety, reactogenicity, and… | Human vaccines & immunotherapeutics 2026-08-16 13:01:41 | Source |
| type B (Hib) necrotizing soft tissue infection (NSTI) in a vaccinated… Escalation Therapies Group · PMID 42446531 | Sclérose en plaques | Neuroprotection · Traitement symptomatique | Publication | PubMed | Voir la publication source Necrotizing soft tissue infection (NSTI) caused by type B (Hib) is rare and life-threatening. We report severe monomicr… | International journal of circumpolar health 2026-08-16 13:01:41 | Source |
| Application of high-intensity focused ultrasound in gynaecological di… Other treatment · PMID 41867046 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source High-intensity focused ultrasound (HIFU), a noninvasive treatment method, has attracted increasing attention in recent… | International journal of hyperthermia : the official j… 2026-08-16 13:01:30 | Source |
| On-label persistence in psoriasis after switching to guselkumab, tumo… Other treatment · PMID 41732098 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source To compare on-label persistence among adults with psoriasis who switched from other advanced therapies to guselkumab ve… | The Journal of dermatological treatment 2026-08-16 13:01:30 | Source |
| Sequential axitinib and survivin vaccination unlock curative PD-1 imm… Other treatment · PMID 42343214 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source Despite significant progress achieved by combining VEGFR tyrosine-kinase inhibitors (TKIs) with immune checkpoint inhib… | Oncoimmunology 2026-08-16 13:01:30 | Source |
| A multiple ascending dose, phase1b study to evaluate safety, tolerabi… No Drug · PMID 42594832 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source Lesigercept (also known as YH35324) has shown favorable safety, dose-proportional pharmacokinetics (PK), and sustained… | International immunopharmacology 2026-08-16 13:01:29 | Source |
| Discovery, development, and characterization of SPY002 and SPY072, tw… No Drug · PMID 42106953 | Sclérose en plaques | Immunomodulation | Publication | PubMed | Voir la publication source TL1A is a proinflammatory cytokine in the tumor necrosis factor (TNF) superfamily that signals via DR3 on T helper cell… | mAbs 2026-08-16 13:01:29 | Source |
| Efficacy and safety of adjunctive orexin receptor antagonist therapy… No Drug · PMID 42309189 | Sclérose en plaques | Traitement symptomatique · Thérapie génique | Publication | PubMed | Voir la publication source A substantial proportion of adults with major depressive disorder (MDD) exhibit an inadequate response to selective ser… | Journal of affective disorders 2026-08-16 13:01:29 | Source |
| A new, glycoengineered form of anti-CD20 monoclonal antibody, in trea… monoclonal CD-20 antibodies · PMID 41928770 | Sclérose en plaques | Ralentissement de la progression · Immunomodulation | Publication | PubMed | Voir la publication source B-cell depletion with anti-CD20 monoclonal antibody (mAb) represents a novel and highly effective treatment for patient… | Therapeutic advances in neurological disorders 2026-08-16 13:01:28 | Source |
| Dermatologic Adverse Events Associated with T-Cell Engager Therapy. monoclonal CD-20 antibodies · PMID 42228307 | Cancer | Immunomodulation | Publication | PubMed | Voir la publication source T-cell engager therapies, including bispecific T-cell engagers and the immune-mobilizing monoclonal T-cell receptor aga… | American journal of clinical dermatology 2026-08-16 13:01:28 | Source |
| The placebo effect on depressive symptoms and brain age in patients w… dim red light · PMID 41544307 | Sclérose en plaques | Traitement symptomatique | Publication | PubMed | Voir la publication source Depression is associated with accelerated brain aging. Bright light therapy (BLT) shows promise in treating depression… | Journal of psychiatric research 2026-08-16 13:01:25 | Source |
| Lighting in intensive care units: A systematic review of patient outc… bright light therapy · PMID 42217522 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source Patients admitted to ICUs are frequently exposed to disrupted light-dark cycles due to limited daylight exposure and in… | Intensive & critical care nursing 2026-08-16 13:01:24 | Source |
| Pharmacologic management of postoperative sleep disturbance in breast… bright light therapy · PMID 42591116 | Cancer | Traitement symptomatique · Thérapie génique | Publication | PubMed | Voir la publication source Postoperative sleep disturbance (PSD) is a common yet underrecognized complication after breast cancer surgery and is a… | Frontiers in pharmacology 2026-08-16 13:01:24 | Source |
| A UHPLC-MS/MS method for the simultaneous quantification of BTK inhib… Orelabrutinib · PMID 42453028 | Sclérose en plaques · Sclérose latérale amyotrophique · Sclérose en p… | Immunomodulation | Publication | PubMed | Voir la publication source Bruton's tyrosine kinase inhibitors (BTKis, ibrutinib, zanubrutinib, orelabrutinib) are key targeted therapies for B-ce… | Bioanalysis 2026-08-16 13:01:21 | Source |
| Effectiveness of biological drugs in the treatment of xerostomia and… Remibrutinib · PMID 41805268 | Sclérose en plaques | Thérapie génique | Publication | PubMed | Voir la publication source Sjögren disease (SjD) can involve systemic complications. Advances in understanding its pathophysiology and the develop… | Journal of the American Dental Association (1939) 2026-08-16 13:01:21 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||